Hansoh jumps most in 19 months on annual profit beat, Citi lifts target price

Shares of China's Hansoh Pharmaceutical Group 3692.HK jump 8.6% to HK$35.94, on track for biggest one-day pct gain since August 2024

Stock hits the highest point since February 24 in the third straight session of gains; top pct gainer in the Hang Seng Biotech Index .HSBIO, which slips 0.2%

Hansoh, a Roche ROG.S partner, reports a 27% y/y rise in 2025 annual profit, beating market expectations and boosted by income from innovative medicines and business development deals

Citi maintains "buy" rating on Hansoh and lifts target price to HK$49 from HK$45 as it raises FY26/27E revenue forecasts by 8%/9% to reflect latest sales trend and business development collaboration revenue

YTD, stock down 1.4%, benchmark Hang Seng Index .HSI down 3.7%